| Literature DB >> 30209758 |
Maryam Rameshk1,2, Fariba Sharififar1, Mitra Mehrabani1, Abbas Pardakhty3, Alireza Farsinejad4,5, Mehrnaz Mehrabani6.
Abstract
PURPOSE: In Traditional Persian Medicine (TPM), different natural treatments have been suggested for skin damages such as Narcissus tazetta L. bulb application. New drug delivery systems such as niosomes have shown considerable increase transdermal drug delivery through stratum corneum, the main barrier against substances transport into skin. The aim of this study is preparation of niosomal formulations from N. tazetta bulb extract and evaluation of its in vitro wound healing effect.Entities:
Keywords: Human dermal fibroblast; Narcissus tazetta; Niosome; Traditional Persian medicine; Wound healing
Year: 2018 PMID: 30209758 PMCID: PMC6154482 DOI: 10.1007/s40199-018-0211-7
Source DB: PubMed Journal: Daru ISSN: 1560-8115 Impact factor: 3.117
Different niosomal formulations prepared for PEN encapsulation
| Formulation code | ST60 35:35 | ST60 30:30 | ST60 25:25 | Chol | Amount of extract (μg/ml) | W/M | Mean volume diameter (μm) ± SD |
|---|---|---|---|---|---|---|---|
| F1 | ✓ | – | – | 30 | 3% | W | 12.06 ± 4.45 |
| F2 | – | ✓ | – | 40 | 3% | W | 8.18 ± 0.06 |
| F3 | – | – | ✓ | 50 | 3% | W | 8.37 ± 0.01 |
| F4 | ✓ | – | – | 30 | 3% | M | 7.51 ± 0.14 |
| F5 | – | ✓ | – | 40 | 3% | M | 21.82 ± 10.98 |
| F6 | – | – | ✓ | 50 | 3% | M | 14.25 ± 0.16 |
| F7 | ✓ | – | – | 30 | 5% | W | 5.71 ± 0.2 |
| F8 | – | ✓ | – | 40 | 5% | W | 8.01 ± 0.11 |
| F9 | – | – | ✓ | 50 | 5% | W | 7.52 ± 0.03 |
| F10 | ✓ | – | – | 30 | 5% | M | 8.31 ± 0.42 |
| F11 | – | ✓ | – | 40 | 5% | M | 10.4 ± 1.75 |
| F12 (LS-HC-H/M) | – | – | ✓ | 50 | 5% | M | 9.84 ± 0.35 |
S, Span; T, Tween; Chol, Cholesterol; PEN, Percolated extract of N. tazetta bulb; W, PEN in distilled water solution; M, methanolic PEN
Fig. 1Optical micrographs of 12 niosomes formulations (×400 magnification). (Scale bar: 10 μm)
Fig. 2F8 and F10 formulations were chosen for physical stability of NSVs at refrigerator temperature (4–8 °C) for 3-month storage duration. High physical stability was observed for both formulations
The mean volume diameter of vesicles in 2 formulations (F8 & F10) at different time intervals after preparation and storage at 4–8 °C and the mean of volume diameter of vesicles in 3 formulations (F3, F6, F9) at different time and temperature intervals after preparation
| Formulation code | Mean volume diameter (μm) ± SD/4–8 °C | Mean volume diameter (μm) ± SD/25 ± 2 °C-30% RH | Mean volume diameter (μm) ± SD/40 ± °C-70% RH | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 h | 15 days | 1 month | 3 months | 48 h | 15 days | 1 month | 3 months | 48 h | 15 days | 1 month | 3 months | |
| F3 | 8.37 ± 0.01 | 8.48 ± 0.11 | 8.41 ± 0.05 | 8.87 ± 0.49 | 8.37 ± 0.01 | 9.06 ± 0.14 | 9.81 ± 0.28 | 15.28 ± 0.60 | 8.37 ± 0.01 | 12.74 ± 0.20 | 14.09 ± 0.26 | 19.16 ± 0.14 |
| F6 | 14.25 ± 0.16 | 14.43 ± 0.47 | 15.83 ± 1.00 | 14.31 ± 0.46 | 14.25 ± 0.16 | 14.07 ± 0.36 | 12.49 ± 0.46 | 12.52 ± 0.20 | 14.25 ± 0.16 | 8.63 ± 0.21 | 8.36 ± 0.14 | 8.85 ± 0.14 |
| F8 | 8.01 ± 0.11 | 7.90 ± 0.06 | 7.88 ± 0.28 | 7.63 ± 0.06 | – | – | – | – | – | – | – | – |
| F9 | 7.52 ± 0.03 | 7.57 ± 0.15 | 7.55 ± 0.06 | 7.27 ± 0.14 | 7.52 ± 0.03 | 7.81 ± 0.08 | 7.68 ± 0.12 | 12.02 ± 0.59 | 7.52 ± 0.03 | 9.33 ± 0.32 | 10 ± 0.28 | 14.80 ± 0.83 |
| F10 | 8.31 ± 0.42 | 8.87 ± 0.0.01 | 8.76 ± 0.17 | 8.36 ± 0.27 | – | – | – | – | – | – | – | – |
| Empty niosome ST60-(S:25, T:25, Chol:50) | 8.4 ± 0.4 | 9.00 ± 0.19 | 8.88 ± 006 | 8.38 ± 0.31 | 8.4 ± 0.4 | 8.86 ± 0.23 | 9.36 ± 0.8 | 7.67 ± 0.31 | 8.4 ± 0.4 | 8.65 ± 0.07 | 8.80 ± 0.02 | 7.65 ± 0.33 |
Comparison the encapsulation efficiency (%) of various formulations (F3, F6, and F9) in refrigerator, room temperature and 40 °C
| Formulation code | Encapsulation efficiency (%) ± SD/4–8 °C | Encapsulation efficiency (%) ± SD/25 ± 2 °C-30% RH | Encapsulation efficiency (%) ± SD/40 ± °C-70% RH | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 h | 15 days | 1 month | 3 month | 48 h | 15 days | 1 month | 3 month | 48 h | 15 days | 1 month | 3 month | |
| F3 | 80.2 ± 0.4 | 76.9 ± 2.4 | 74.4 ± 1.1 | 70.4 ± 1.7 | 80.2 ± 0.4 | 75.2 ± 1.7 | 70.5 ± 1.0 | 64.8 ± 1.2 | 80.2 ± 0.4 | 71.6 ± 1.0 | 63.2 ± 16.5 | 52.1 ± 0.7 |
| F6 | 70.1 ± 6.6 | 65.8 ± 1.7 | 59.8 ± 4.1 | 58.9 ± 5.7 | 70.1 ± 6.6 | 60.2 ± 11.8 | 58.4 ± 4.8 | 56.3 ± 3.2 | 70.1 ± 6.6 | 63.5 ± 0.2 | 62.8 ± 3.0 | 55.7 ± 1.7 |
| F9 | 88.8 ± 1.1 | 86.2 ± 2.7 | 83.2 ± 1.2 | 75.7 ± 3.1 | 88.8 ± 1.1 | 81.8 ± 3.4 | 75.2 ± 1.2 | 68.1 ± 1.6 | 88.8 ± 1.1 | 76.4 ± 4.6 | 68.5 ± 1.1 | 54.8 ± 1.0 |
Fig. 3Comparison of physical stability of selected formulations including F3, F6 and F9 in refrigerator, room temperature and 40 °C. F9 showed the most physical stability characterizations depicted as the least volume diameter changes
Fig. 4a and b SEM photomicrograph images, c and d TEM photomicrograph images, e and f Morphological micrographs (×400 magnification) of F9 formulation
Fig. 5Proliferating effect of different concentrations of F9 (the best niosomal formulation of PEN) on human dermal fibroblasts (HDF) using Neutral Red assay. 1 × 104 (HDF) were seeded in 96 wells plate. After incubation in 37 °C and 5% CO2 for 24 h, treated with various concentrations of F9 and untreated cells used as control. Proliferation effect was determined using Neutral Red assay after 48 h and absorbance was measured at 540 nm with Eliza reader. The value from the baseline control group was set at 100%. (***) significantly increased cell proliferation (p < 0.05). The results were expressed as mean ± S.D.
Fig. 6Gap widths of scratch of different concentrations of F9 (a) and PEN (b) were analyzed with ImageJ software in comparison of untreated cells as the control and cells with FBS 10% as the positive control. (***) significantly reduced the gap width compared to the control group (p < 0.05). c Comparison of wound healing effect of F9, PEN, control and positive control, using scratch assay on human dermal fibroblast (HDF)